Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (20)
Semelhante a Madsen
Semelhante a Madsen (20)
Mais de The Ohio State University Wexner Medical Center
Mais de The Ohio State University Wexner Medical Center (20)
Último
Último (20)
Madsen
- 1. Infrastructure to Enable P4 Medicine: Investing in Innovative Personalized Health Solutions OSU Annual Personalized Health Care National ConferenceOctober 6, 2011
- 3. International Comparison Health Expenditure, 1980–2008 Total expenditures on healthas percent of GDP Average spending on healthper capita ($US PPP) Source: OECD Health Data 2010 (Oct. 2010).
- 4. An Aging Global Population
- 5. Number of Practicing Physicians per 1,000 Population, 2008 * 2007. ** 2006. Source: OECD Health Data 2010 (Oct. 2010).
- 6. Average Annual Growth Rate of Practicing Physicians per 1,000 Population, 1998–2008 Percent * 1997–2007. ** 1996–2006. Source: OECD Health Data 2010 (Oct. 2010).
- 7. Asthma Admission Rates per 100,000 Population Age 15 and Older, 2007 * 2006. ** 2005. *** Among countries shown. Source: OECD Health Care Quality Indicators Data 2009.
- 8. Diabetes Acute Complications Admission Rates per 100,000 Population Age 15 and Older, 2007 * 2006. ** 2005. *** Among countries shown. Source: OECD Health Care Quality Indicators Data 2009.
- 9. Congestive Heart Failure Admission Rates per 100,000 Population Age 15 and Older, 2007 * 2006. ** 2005. *** Among countries shown. Source: OECD Health Care Quality Indicators Data 2009.
- 10. * 2006. ** 2005. *** Among countries shown. Source: OECD Health Care Quality Indicators Data 2009. Diabetes Lower Extremity Amputation Rates per 100,000 Population Age 15 and Older, 2007*
- 12. Create deeper engagement with health consumer
- 13. Provide clear, simple tools to the provider
- 14. Make it better, cheaper and faster The Big Need The Six Trillion Dollar Man
- 15. Two Key Innovations of Our Generation Transforming Personalized Health
- 16. The Physic view of Personalized Health Health is inherently personal and… ...one size does not fit all. Personalized health uses precise tools and technologiesto measure an individual’s unique characteristics to enhance health.
- 17. Where is Health Being Personalized? Clinical Medicine Drug Development Consumer Products Diagnostics Insurance PBMs Clinical Nutrition Food Safety
- 18. What Does it Look Like? Clinical Medicine Consumer Products Diagnostics Drug Development Insurance PBMs Clinical Nutrition Food Safety
- 19. It also looks like this 16
- 20. And this.. 17
- 21. And this… 18
- 22. And this… 19
- 23. And this.. 20
- 24. And this.. 21
- 26. Supported by validated science
- 28. Informs meaningful decision about intervention (treatment/procedure) or behavior
- 30. Provides significant incremental benefit over use of existing tools
- 31. Demonstrates near-term benefit or cost-effectiveness
- 32. Alignment of Patient, Physician and Payer
- 33. Path to regulatory approval and reimbursement
- 36. Mental Health
- 39. Cancer
- 41. Fitness
- 44. $11M Series B in 3/11 for PGx analysis of depression and anxiety therapies (Mental Health)
- 45. $30M Series C in 10/10 for diagnosis of Tissues of Origin (Cancer)
- 46. $18M Series A in 9/10 for pre-pregnancy screening (Reproductive Health)
- 47. $13M Series B in 7/11 for POC diagnostics for bloodstream infections (Infectious Disease)
- 48. $27M Series B in 7/11 for POC diagnostics for STDs (Infectious Disease)
- 49. $23M Series D in 8/11 for POC diagnostics for candida (Infectious Disease)
- 50. $18M Series B in 8/11 for inflammatory biomarkers for CVD (Cardiovascular)
- 51. $18M Series C in 9/11 for inflammatory biomarkers for RA (Autoimmune)VC Money Backing Innovation
- 52. How do I feel?
Notas do Editor
- Zelboraf – U.S. Food and Drug Administration (FDA) approved Zelboraf for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by the concurrently-approved 4800 BRAF V600 Mutation Test, a diagnostic test developed by Roche to identify patients eligible for treatment. “The FDA approval of Zelboraf marks a major step forward in personalizing the treatment of metastatic melanoma, a devastating disease that until this year had limited approved treatment options,” said Hal Barron, M.D., chief medical officer and head, Global Product Development.